Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Westenberg
PIPR
David Westenberg
Wall Street Analyst
★★★☆☆
#1681
on 13Foresight · ranked by our own returns
45%
Success Rate
+72.8%
Average Return
15 of 33 calls profitable · +69.5% vs benchmark
📈 Across the calls we could measure, roughly 45% of David Westenberg's ratings turned a profit when each position was held for 1 year — averaging +72.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

86 Buy 52 Hold 0 Sell
David's Stock Coverage 39 ratings · 2026-06-18
Company Date Position Consensus Price Target 1-Yr Return
A
Agilent
Jun 11, 2026 HOLD Strong Buy
+5.4% avg upside
32 analysts
$150.00
18.67% Upside
·
TECH
Bio-Techne
Jun 11, 2026 HOLD Strong Buy
+43.3% avg upside
21 analysts
$65.00
13.61% Upside
+3.7%
DHR
Danaher
Jun 11, 2026 HOLD Strong Buy
+21.5% avg upside
45 analysts
$200.00
12.33% Upside
+0.3%
IT:DIA
DiaSorin S.p.A.
Jun 11, 2026 HOLD Hold
+54.0% avg upside
9 analysts
$75.00
17.70% Upside
·
FR:BIM
bioMerieux
Jun 11, 2026 HOLD Buy
+55.6% avg upside
12 analysts
$80.00
18.39% Upside
·
WAT
Waters
Jun 11, 2026 HOLD Strong Buy
+3.2% avg upside
30 analysts
$400.00
12.75% Upside
-0.5%
TMO
Thermo Fisher
Jun 11, 2026 HOLD Strong Buy
+27.5% avg upside
38 analysts
$510.00
10.16% Upside
-0.6%
TWST
Twist Bioscience
Jun 11, 2026 BUY Strong Buy
-24.0% avg upside
14 analysts
$85.00
1.43% Downside
+14.7%
GRAL
GRAIL Inc
Jun 02, 2026 HOLD Buy
+6.5% avg upside
8 analysts
$56.00
8.29% Downside
-2.7%
GH
Guardant Health
May 28, 2026 BUY Strong Buy
-5.0% avg upside
30 analysts
$135.00
3.04% Upside
-2.5%
NTRA
Natera
May 12, 2026 BUY Strong Buy
+9.1% avg upside
26 analysts
$249.00
8.40% Upside
+10.9%
TEM
Tempus AI, Inc. Class A
May 12, 2026 HOLD Strong Buy
+37.5% avg upside
19 analysts
$58.00
17.63% Upside
+7.7%
CAI
Caris Life Sciences, Inc.
May 12, 2026 HOLD Strong Buy
+57.7% avg upside
20 analysts
$21.00
15.53% Upside
-1.6%
ADPT
Adaptive Biotechnologies
May 12, 2026 BUY Strong Buy
+22.9% avg upside
14 analysts
$20.00
16.63% Upside
+29.1%
MYGN
Myriad Genetics
May 12, 2026 BUY Hold
+326.2% avg upside
24 analysts
$8.50
89.37% Upside
-3.9%
PACB
Pacific Biosciences
May 08, 2026 HOLD Buy
+225.5% avg upside
14 analysts
$2.00
44.91% Upside
-20.6%
CTKB
Cytek Biosciences
May 08, 2026 BUY Buy
+45.1% avg upside
5 analysts
$7.50
93.60% Upside
-9.1%
TXG
10x Genomics
May 08, 2026 HOLD Buy
-24.1% avg upside
18 analysts
$20.00
43.36% Downside
+47.0%
BLLN
BillionToOne, Inc. Class A
May 07, 2026 BUY Strong Buy
+20.2% avg upside
8 analysts
$130.00
26.79% Upside
+8.8%
FLGT
Fulgent Genetics
May 05, 2026 HOLD Buy
+144.8% avg upside
7 analysts
$15.00
16.82% Downside
+6.1%
WGS
GeneDx Holdings
May 05, 2026 BUY Strong Buy
+39.8% avg upside
9 analysts
$130.00
125.21% Upside
+77.7%
ILMN
Illumina
May 01, 2026 BUY Buy
-9.2% avg upside
30 analysts
$170.00
5.15% Upside
+17.2%
TRUP
Trupanion
May 01, 2026 BUY Strong Buy
+72.4% avg upside
19 analysts
$45.00
90.68% Upside
-2.1%
NEO
NeoGenomics
Apr 30, 2026 BUY Strong Buy
+46.6% avg upside
17 analysts
$13.00
20.07% Upside
+20.4%
LH
Labcorp Holdings
Feb 24, 2026 HOLD Strong Buy
+0.7% avg upside
36 analysts
$300.00
17.66% Upside
-10.4%
IDXX
Idexx Laboratories
Feb 09, 2026 HOLD Buy
+32.1% avg upside
17 analysts
$750.00
35.28% Upside
-12.3%
ZTS
Zoetis
Jan 22, 2026 HOLD Buy
+74.3% avg upside
22 analysts
$135.00
73.51% Upside
-37.6%
ELAN
Elanco Animal Health
Jan 22, 2026 BUY Strong Buy
+25.3% avg upside
18 analysts
$30.00
25.08% Upside
-2.7%
NEOG
Neogen
Jan 12, 2026 HOLD Buy
+157.5% avg upside
6 analysts
$10.00
9.94% Upside
-7.3%
DGX
Quest Diagnostics
Oct 27, 2025 HOLD Buy
-13.1% avg upside
33 analysts
$200.00
3.52% Upside
+14.1%
GB:ONT
Oxford Nanopore Technologies PLC
Sep 03, 2025 BUY Strong Buy
+80.6% avg upside
6 analysts
$190.00
65.76% Upside
·
IMDX
Insight Molecular Diagnostics
Nov 13, 2023 HOLD Buy
+1.1% avg upside
10 analysts
$3.00
43.07% Downside
·
RNLXY
Renalytix
Oct 04, 2021 BUY Strong Buy
+800.3% avg upside
5 analysts
$28.00
2245.04% Upside
·
PAHC
Phibro Animal Health
May 23, 2019 HOLD Hold
+20.3% avg upside
10 analysts
-15.2%
RGEN
Repligen
Dec 17, 2018 BUY Strong Buy
+27.5% avg upside
25 analysts
$65.00
51.05% Downside
+2439.4%
PETS
Petmed Express
Jun 15, 2018 HOLD Sell
+690.3% avg upside
6 analysts
-58.2%
BIO
Bio-Rad Laboratories
Feb 16, 2018 HOLD Buy
+22.8% avg upside
8 analysts
·
QDEL
QuidelOrtho
Jan 04, 2018 BUY Buy
+193.2% avg upside
13 analysts
$52.00
290.01% Upside
+6.8%
CENT
Central Garden Pet
Dec 07, 2017 BUY Buy
+3.6% avg upside
9 analysts
$47.00
8.56% Upside
-18.5%
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
David Westenberg — Frequently Asked Questions
How accurate are David Westenberg's stock ratings?
Based on the calls 13Foresight could measure, about 45% of David's ratings were profitable over a one-year hold, with an average return of +72.8% per rating, or +69.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Westenberg is currently ranked #1681 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on A, TECH, DHR, IT:DIA, FR:BIM, WAT, TMO, TWST, GRAL, GH, NTRA, TEM and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.